logo
Share SHARE
FONT-SIZE Plus   Neg

Bristol-Myers Reports Positive Results From Study On Cancer Drug

Bristol-Myers Squibb Company (BMY) Saturday said an experimental drug showed positive results in patients suffering from melanoma, kidney cancer and lung cancer in a preliminary clinical trial.

Results of the Phase-I study on anti-PD-1 or BMS-936558 in patients with previously-treated non small-cell lung cancer, metastatic melanoma and renal cell carcinoma were encouraging as they showed improvement in patients. The clinical trial added to the understanding of the potential of immuno-oncology as a therapeutic approach in the treatment of cancer, the pharmaceutical firm said.

"Immuno-oncology is a prioritized area of research and development at Bristol-Myers Squibb and we plan to initiate registrational studies for anti-PD-1 in non small-cell lung cancer and renal cell carcinoma this year and late 2012, early 2013 for metastatic melanoma," Brian Daniels, senior vice president of Global Development and Medical Affairs t Bristol-Myers Squibb, said.

Anti-PD-1 is a fully-human antibody that targets the inhibitory receptor expressed on activated T-cells called PD-1 or programmed death-1.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
French aircraft maker Dassault Aviation SA said Wednesday that following repeated delays, it has terminated a contract with French defense company Safran for its Silvercrest engine that was intended to power Dassault's Falcon 5X business jet. Walt Disney Co. has agreed to buy certain assets of Rupert Murdoch's Twenty-First Century Fox, Inc. for about $52.4 billion in stock, the two companies said Thursday. Immediately prior to the acquisition by Disney, 21st Century Fox will separate the Fox Broadcasting network, Fox News Channel, Fox Business Network, FS1, FS2 and Big Ten Network into a newly listed company that will be spun off. Crypto Co., engaged in the digital currencies and blockchain sector, announced its plans to execute a 10-for-1 stock split, citing the significant growth in the value and demand for its shares amid the ongoing digital currency market boost. CEO Mike Poutre said, ""We are aware of the recent fluctuation in our stock, and want to see orderly market activity surrounding the trading of our stock."
comments powered by Disqus
Follow RTT